PubRank

Reply to: 'No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease'.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 32387073)

Published in J Hepatol on May 06, 2020

Authors

Dong Ji1, Jing Xu2, Enqiang Qin1, Dawei Zhang1, Gregory Cheng3, Yudong Wang3, George Lau4

Author Affiliations

1: The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China.
2: Fuyang Second People's Hospital, Fuyang, Anhui 236000, China.
3: Humanity and Health Clinical Trial Center, Humanity & Health Medical Group, Hong Kong SAR, China.
4: The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China; Humanity and Health Clinical Trial Center, Humanity & Health Medical Group, Hong Kong SAR, China. Electronic address: gkklau@hnhmgl.com.

Articles cited by this ↗

No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease. J Hepatol (2020) 1.38

Articles by these authors ⇆

Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J Hepatol (2020) 4.99

Reply to: 'NAFLD or comorbidities, that is the question'. J Hepatol (2020) 0.75

Reply to: 'Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis'. J Hepatol (2020) 0.75